Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis
Kennedy, GA; Tey, SK; Buizen, L; Varelias, A; Gartlan, KH; Curley, C; Olver, SD; Chang, KS; Butler, JP; Misra, A; Subramoniapillai, E; Morton, AJ; Durrant, S; Henden, AS; Moore, J; Ritchie, D; Gottlieb, D; Cooney, J; Paul, SK; Hill, GR
(2021), Blood, 1970-1979
International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses
Solves, P; Lozano, M; Zhiburt, E; Velasco, JA; Perez-Corral, AM; Monsalvo-Saornil, S; Yamazaki, S; Okazaki, H; Selleng, K; Aurich, K; Kruger, W; Buser, A; Holbro, A; Infanti, L; Stehle, G; Pierelli, L; Matteocci, A; Rigacci, L; De Vooght, KMK; Kuball, JHE; Fielding, KL; Westerman, DA; Wood, EM; Cohn, CS; Johnson, A; Koh, MBC; Qadir, D; Cserti-Gazdewich, C; Daguindau, E; Angelot-Delettre, F; Tiberghien, P; Wendel-Neto, S; Fachini, RM; Morton, S; Craddock, C; Lumley, M; Antoniewicz-Papis, J; Halaburda, K; Letowska, M; Dunbar, N
(2021), Vox Sang., E25-E43
DOI: 10.1111/vox.13021
Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia
Gordon, SF; Clothier, HJ; Morgan, H; Buttery, JP; Phuong, LK; Monagle, P; Chunilal, S; Wood, EM; Tran, H; Szer, J; Crawford, NW
(2021), Vaccine, 7052-7057
Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience
Vazirani, J; Routledge, D; Snell, GI; Watson, D; Paraskeva, M; Westall, GP; Harrison, SJ
(2021), Transplant. Proc., 296-302
Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program
El Fakih, R; Greinix, H; Koh, M; Shaw, B; Mohty, M; Al Nahedh, M; Saber, W; Kharfan-Dabaja, MA; Perales, MA; Savani, BN; Majhail, NS; Passweg, JR; Sureda, A; Ahmed, SO; Gluckman, E; Riches, M; El-Jawahri, A; Rondelli, D; Srivastava, A; Faulkner, L; Atsuta, Y; Ballen, KK; Rasheed, W; Okamoto, S; Seber, A; Chao, N; Kroger, N; Kodera, Y; Szer, J; Hashmi, SK; Horowitz, MM; Weisdorf, D; Niederwieser, D; Aljurf, M
(2021), Transpl. Cell. Ther.
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy
Orfali, N; Zhang, MJ; Allbee-Johnson, M; Boelens, JJ; Artz, AS; Brunstein, CG; McNiece, IK; Milano, F; Abid, MB; Chee, L; Diaz, MA; Grunwald, MR; Hematti, P; Hsu, JM; Lazarus, HM; Munshi, PN; Prestidge, T; Ringden, O; Rizzieri, D; Riches, ML; Seo, S; Solh, M; Solomon, S; Szwajcer, D; Yared, J; van Besien, K; Eapen, M
(2021), Transpl. Cell. Ther.
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation
Farhadfar, N; Dias, A; Wang, T; Fretham, C; Chhabra, S; Murthy, HS; Broglie, L; D'Souza, A; Gadalla, SM; Gale, RP; Hashmi, S; Al-Homsi, AS; Hildebrandt, GC; Hematti, P; Rizzieri, D; Chee, L; Lazarus, HM; Bredeson, C; Jaimes, EA; Beitinjaneh, A; Bashey, A; Prestidge, T; Krem, MM; Marks, DI; Benoit, S; Yared, JA; Nishihori, T; Olsson, RF; Freytes, CO; Stadtmauer, E; Savani, BN; Sorror, ML; Ganguly, S; Wingard, JR; Pasquini, M
(2021), Transpl. Cell. Ther., 410-422
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Oran, B; Ahn, KW; Fretham, C; Beitinjaneh, A; Bashey, A; Pawarode, A; Wirk, B; Scott, BL; Savani, BN; Bredeson, C; Weisdorf, D; Marks, DI; Rizzieri, D; Copelan, E; Hildebrandt, GC; Hale, GA; Murthy, HS; Lazarus, HM; Cerny, J; Liesveld, JL; Yared, JA; Yves-Cahn, J; Szer, J; Verdonck, LF; MahmoudAljurf; van der Poel, M; Litzow, M; Kalaycio, M; Grunwald, MR; AngelDiaz, M; Sabloff, M; Kharfan-Dabaja, MA; Majhail, NS; Farhadfar, N; Reshef, R; Olsson, RF; Gale, RP; Nakamura, R; Seo, S; Chhabra, S; Hashmi, S; Farhan, S; Ganguly, S; Nathan, S; TaigaNishihori; Jain, T; VaibhavAgrawal; Bacher, U; Popat, U; Saber, W
(2021), Transpl. Cell. Ther.
Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation
Worel, N; Shaw, BE; Aljurf, M; Koh, M; Seber, A; Weisdorf, D; Schwartz, J; Galeano, S; Kodera, Y; Eldridge, PW; Hashmi, S; Atsuta, Y; Szer, J; Saber, W; Niederwieser, D; Greinix, HT
(2021), Transpl. Cell. Ther.
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults
Chee, L
(2021), Transpl. Cell. Ther., 953-954
Red blood cell transfusion in patients with anti-Yt(a)
Wong, SM; Cawthorne, T; Dennington, PM; Hong, FS
(2021), Transfusion, 379-384
DOI: 10.1111/trf.16239
Myeloid somatic mutation panel testing in myeloproliferative neoplasms
Ross, DM; Thomson, C; Hamad, N; Lane, SW; Manos, K; Grigg, AP; Guo, B; Erber, WN; Scott, A; Viiala, N; Chee, L; Latimer, M; Tate, C; Grove, C; Perkins, AC; Blombery, P
(2021), Pathology, 339-348
Immature platelet fraction as a predictor of platelet count recovery following allogeneic bone marrow
Grabek, J; D'Elia, N; Kelsey, G
(2021), Pathology, 493-497
Identification and quantitation of blasts in myeloid malignancies with marrow fibrosis or marrow hypoplasia and CD34 negativity
Nedumannil, R; Sim, S; Westerman, D; Juneja, S
(2021), Pathology, 795-798
Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy
Leitinger, EJ; Wright, RM; Nelson, N; Anderson, MA; Juneja, S
(2021), Pathology, 926-929
Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms
George, TI; Bajel, A
(2021), Pathology, 312-327
CAR-T cell therapy: practical guide to routine laboratory monitoring
Selim, AG; Minson, A; Blombery, P; Dickinson, M; Harrison, SJ; Anderson, MA
(2021), Pathology, 408-415
Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding
Kuzich, JA; Heynemann, S; Geoghegan, N; Evelyn, C; O'Mahoney, S; Wilson, S; Campbell, J; Rogers, K; Solomon, B; Westerman, D; Pasricha, SR
(2021), Pathology, 608-612
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P; Szer, J; Weitz, I; Roth, A; Hochsmann, B; Panse, J; Usuki, K; Griffin, M; Kiladjian, JJ; de Castro, C; Nishimori, H; Tan, L; Hamdani, M; Deschatelets, P; Francois, C; Grossi, F; Ajayi, T; Risitano, A; de la Tour, RP
(2021), N. Engl. J. Med., 1028-1037
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Giuffrida, L; Sek, K; Henderson, MA; Lai, JY; Chen, AXY; Meyran, D; Todd, KL; Petley, EV; Mardiana, S; Molck, C; Stewart, GD; Solomon, BJ; Parish, IA; Neeson, PJ; Harrison, SJ; Kats, LM; House, IG; Darcy, PK; Beavis, PA
(2021), Nat. Commun.
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study
Lim, C; Sinha, P; Harrison, SJ; Quach, H; Slavin, MA; Teh, BW
(2021), Mycoses, 30-34
DOI: 10.1111/myc.13178
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
Hogg, SJ; Motorna, O; Cluse, LA; Johanson, TM; Coughlan, HD; Raviram, R; Myers, RM; Costacurta, M; Todorovski, I; Pijpers, L; Bjelosevic, S; Williams, T; Huskins, SN; Kearney, CJ; Devlin, JR; Fan, Z; Jabbari, JS; Martin, BP; Fareh, M; Kelly, MJ; Dupere-Richer, D; Sandow, JJ; Feran, B; Knight, D; Khong, T; Spencer, A; Harrison, SJ; Gregory, G; Wickramasinghe, VO; Webb, AI; Taberlay, PC; Bromberg, KD; Lai, A; Papenfuss, AT; Smyth, GK; Allan, RS; Licht, JD; Landau, DA; Abdel-Wahab, O; Shortt, J; Vervoort, SJ; Johnstone, RW
(2021), Mol. Cell, 2183
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study
Yee, K; Papayannidis, C; Vey, N; Dickinson, MJ; Kelly, KR; Assouline, S; Kasner, M; Seiter, K; Drummond, MW; Yoon, SS; Lee, JH; Blotner, S; Jukofsky, L; Pierceall, WE; Zhi, JG; Simon, S; Higgins, B; Nichols, G; Monnet, A; Muehlbauer, S; Ott, M; Chen, LC; Martinelli, G
(2021), Leuk. Res.
Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH
Singh, J; Facey, A; O'Malley, F; Ryland, GL; Blombery, P; Gregory, GP
(2021), Leuk. Lymphoma, 3060-3062
Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL
Jobson, D; McCormack, CJ; Hiscutt, E; Tam, C
(2021), Leuk. Lymphoma, 992-994
Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature
Reynolds, G; Stewart, T; Harrison, SJ; Spencer, A; Teh, BW
(2021), Leuk. Lymphoma, 1271-1274
Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma COMMENT
Minson, A; Dickinson, M
(2021), Leuk. Lymphoma, 2047-2049
The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL
Seymour, JF
(2021), Leuk. Lymphoma, 2299-2302
RT or not RT? The question for early-stage peripheral T-cell lymphoma
Campbell, BA; Khot, A
(2021), Leuk. Lymphoma, 511-513
Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN
Caldwell, I; Byrne, D; Lade, S; Akhurst, T; Minson, A; Dickinson, M; Thompson, E; Scott, C; Blombery, P
(2021), Leuk. Lymphoma, 3521-3525